スポット尿中11-dehydro-Thromboxane B_2レベルによるアスピリン耐性患者のスクリーニングは可能か?

概要

論文の詳細を見る
Thromboxane A_2 (TXA_2) is produced from arachidonic acid by cyclooxygenase-1 (COX-1) in thrombocytes and for the most part is converted to 11-dehydro-thromboxane B_2 (11dTXB_2), the final stable metabolite. Since daily excretion amounts of 11dTXB_2 in urine are well correlated with the degree of inhibition of COX-1 by aspirin, inhibition is evaluated by measuring 11dTXB_2 excretion and this is usually done through 24-hour urine collection. However, as this involves a lot of work, we examined the validity of using spot urine measurements for this purpose. The intra-day variation in urinary 11dTXB_2 levels was studied in five patients who had been taking low-dose aspirin for an extended period. Urinary concentrations of 11dTXB_2 were measured using a commercial enzyme immunoassay kit and the urinary excretion rate of 11dTXB_2 was expressed as the ratio of the concentration of 11dTXB_2 to that of creatinine. The results showed that there was no marked variation in intra-day urinary excretion rates and that the range of variation from 24-hour urine measurements was no more than about 15%. They therefore indicate that spot urine could be used in place 24-hour urine collection for measuring 11dTXB_2 levels.
日本医療薬学会の論文
2006-12-10